Quinupristin/Dalfopristin and linezolid: Spectrum of activity and potential roles in therapy - A status report

Current Clinical Topics in Infectious Diseases

Volumn , Issue 21, 2001, Pages 227-251

  Batts, Donald H ^a   Lavin, Bruce S ^a   Eliopoulos, George M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; DALFOPRISTIN; DRUG DERIVATIVE; LINEZOLID; OXAZOLIDINONE DERIVATIVE; QUINUPRISTIN; VIRGINIAMYCIN;

ADULT; AGED; AREA UNDER THE CURVE; BACTERIAL INFECTION; CHILD; CROSS INFECTION; DRUG COMBINATION; HUMAN; INFANT; MICROBIOLOGICAL EXAMINATION; NEWBORN; REVIEW; TISSUE DISTRIBUTION;

ACETAMIDES; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CHILD; CROSS INFECTION; DRUG COMBINATIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; TISSUE DISTRIBUTION; VIRGINIAMYCIN;

EID: 0035225002     PISSN: 01953842     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (84)

1. Cocito C, Di Giambattista M, Nyssen E, Vannuffel P. 'Inhibition of protein synthesis by streptogramins and related antibiotics. J Antimicrob Chemother 1997;39(suppl A):7-13.
2. Beyer D, Pepper K. The streptogramin antibiotics: update on their mechanism of action. Expert Opin Invest Drugs 1998;7:591-599.
3. Barrière JC, Bouanchaud DH, Paris JM, et al. Antimicrobial activity against Staphylococcus aureus of semisynthetic injectable streptogramins: RP 59500 and related compounds. J Antimicrob Chemother 1992;30(suppl A):1-8.
4. Bouanchaud DH. In vitro and in vivo synergic activity and fractional inhibitory concentration (FIC) of the components of a semisynthetic streptogramin, RP 59500. J Antimicrob Chemother 1992;30(suppl A):95-99.
5. Porse BT, Garrett RA. Sites of interaction of the streptogramin A and B antibiotics in the peptidyl transferase loop of 23S rRNA and the synergism of their inhibitory mechanisms. J Mol Biol 1999;286: 375-387.
6. Nadler H, Dowzicky MJ, Feger C, et al. Quinupristin/dalfopristin: a novel selective-spectrum antibiotic for the treatment of multi-resistant and other gram-positive pathogens. Clin Microbiol Newsletter 1999;21:103-112.
7. Synercid IV. (quinupristin/dalfopristin for injection). Product labeling. July 1999.
8. Jones RN, Ballow CH, Biedenbach DJ, et al. Antimicrobial activity of quinupristin/dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis 1998;30:437-451.
9. Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. Morbid Mortal Weekly Rep 1997;46:765-766.
10. CDC. Reduced susceptibility of Staphylococcus aureus to vancomycin - Japan, 1996. Morbid Mortal Weekly Rep 1997;46:624-626.
11. Tenover FC, Lancaster MV, Hill BC, et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998;36:1020-1027.
12. Hallow CH, Jones RN, Acar JF, et al. Global evaluation of quinupristin/dalfopristin (Q/D) activity against 19,852 gram-positive pathogens: final report of the Global SMART study [abstract]. Proceedings Fifth International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones, Seville, Spain, January 26-28, 2000.
13. Synercid IV. quinupristin/dalfopristin. Scientific monograph. June 1999.
14. Fish DN, Piscitielli SC, Danzinger LH. Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy 1995;15: 279-291.
15. Allignet J, El Solh N. Diversity among the gram-positive acetyltransferases inactivating streptogramin A and structurally related compounds and characterization of a new staphylococcal determinant, vat B. Antimicrob Agents Chemother 1995;39:2027-2036.
16. Rende-Fournier R, Leclercq R, Galimand M, et al. Identification of the satA gene encoding a streptogramin A acetyltransferase in Enterococcus faecium BM4145. Antimicrob Agents Chemother 1993;37:2119-2125.
17. Bozdogan B, Leclercq R. Intrinsic and acquired resistance to dalfopristin (streptogramin A) in Enterococcus spp. [abstract]. Proceedings of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Sept. 28-Oct. 1, 1997. Abstract C-79.
18. Allignet J, Loncle V, El Solh N. Sequence of a staphylococcal plasmid gene, vga, encoding a putative ATP-binding protein involved in resistance to virginiamycin A-like antibiotics. Gene 1992;117:45-51.
19. Matsumura SO, Louie L, Louie M, Simor AE. Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin/dalfopristin in combination with other antimicrobial agents. Antimicrob Agents Chemother 1999;43:2776-2779.
20. Fantin B, Leclercq R, Carry L, Carbon C. Influence of inducible cross-resistance to macrolides, lincosamides and streptogramin B-type antibiotics in Enterococcus faecium on activity of quinupristin/dalfopristin in vitro and in rabbits with experimental endocarditis. Antimicrob Agents Chemother 1997;41:931-935.
21. B-R) [abstract]. Proceedings of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 24-27, 1998. Abstract B76.
22. Vouillamoz J, Entenza JM, Giddey M, et al. Synercid (Syn) alone or combined with cefamandole (Cef) in the treatment (Rx) of experimental endocarditis (EE) due to methicillin-resistant Staphylococcus aureus (MRSA) constitutively resistant to erythromycin (Ery-R) [abstract]. Proceedings of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, Sept. 28-Oct. 1, 1997. Abstract B-27.
23. Chevalier P, Rey J, Rouzier-Panis R, et al. Multiple-dose pharmacokinetics and safety of quinupristin/dalfopristin (Q/D, RP 59500, Synercid) in healthy volunteers [abstract]. Proceedings of the 20th International Congress of Chemotherapy, Sydney, Australia, June 29-July 3, 1997. Abstract 835.
24. Craig W, Ebert S. Pharmacodynamic activities of RP 59500 in an animal infection model [abstract]. Proceedings of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, Oct. 17-20, 1993. Abstract 470.
25. Chin NX, Neu HC. Post-antibiotic effect of the new streptogramin RP 59500. Eur J Clin Microbiol Infect Dis 1992;11:642-643.
26. Boswell FJ, Andrews JM, Wise R. The postantibiotic effect of RP 59500 on Staphylococcus aureus including strains with a raised MBC. J Antimicrob Chemother 1994;33:1219-1222.
27. Lcfebvre P, Geary W, Rey J, et al. Open, comparative study of the pharmacokinetics and safety of a single dose of quinupristin/dalfopristin (Q/D, RP 59500, Synercid) in healthy male and female volunteers [abstract]. Proceedings of the 20th International Congress of Chemotherapy, Sydney, Australia, June 29-July 3, 1997. Abstract 831.
28. Lefebvre P, Rey J, Harding N, et al. Open, comparative study of the pharmacokinetics and safety of a single dose of quinupristin/dalfopristin (Q/D, RP 59500, Synercid) in healthy elderly volunteers and healthy young volunteers [abstract]. Proceedings of the 20th International Congress of Chemotherapy, Sydney, Australia, June 29-July 3, 1997. Abstract 836.
29. Lefebvre P, Rey J, Morganroth J, et al. Open, comparative study of the pharmacokinetics and safety of a single dose of quinupristin/dalfopristin (Q/D, RP 59500, Synercid) in obese and nonobese male subjects [abstract]. Proceedings of the 20th International Congress of Chemotherapy, Sydney, Australia, June 29-July 3, 1997. Abstract 833.
30. Chevalier P, Rey J, Franke H, et al. Open, comparative study of the pharmacokinetics and safety of a single dose of quinupristin/dalfopristin (Q/D, RP 59500, Synercid) in patients with severe chronic renal failure and in healthy volunteers [abstract]. Proceedings of the 20th International Congress of Chemotherapy, Sydney, Australia, June 29-July 3, 1997. Abstract 834.
31. Chevalier P, Key J, Boucher E, et al. Open, comparative study of the pharmacokinetics and safety of a single dose of quinupristin/dalfopristin (Q/D, RP 59500, Synercid) in subjects with hepatic cirrhosis and healthy volunteers [abstract]. Proceedings of the 20th International Congress of Chemotherapy, Sydney, Australia, June 29-July 3, 1997. Abstract 832.
32. Desnottes JF, Diallo N. Cellular uptake and intracellular bactericidal activity of RP 59500 in murine macrophages. J Antimicrob Chemother 1992;30(supplA):107-115.
33. Ballow CH, Geary WJ, Turnak MR, et al. Uptake of quinupristin/dalfopristin (Q/D) into polymorphonuclear leukocytes (PMNs) in normal volun-teers [abstract]. Proceedings of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, Sept. 24-27, 1998. Abstract 46a.
34. Chenoweth CE. Combating vancomycinresistant enterococci. Intern Med 2000;21:10-16.
35. Moellering RC, Linden PK, Reinhardt J, et al. The efficacy and safety of quintipristin/ dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecalis. J Antimicrob Chemother 1999;44:251-261.
36. Miller CB, Gray SL, Linden PK. Outcome of compassionate use of a novel antibiotic, quinupristin/dalfopristin (QD, Synercid), in neutropenic patients with leukemia [abstract]. Blood 1998;92(suppl 1):609a. Abstract 2512.
37. Data on file, Aventis Pharmaceuticals.
38. Baqucro F. Gram-positive resistance: challenge for the development of new antibiotics. J Antimicrob Chemother 1997;39(suppl A):1-6.
39. Nichols RL, Graham DR, Barriere SL, et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. J Antimicrob Chemother 1999; 44:263-273.
40. Srinath L, Kurkimilis E, Prokocimer P, Talbot GH. Quinupristin/dalfopristin (Synercid therapy for methicillin-resistant Staphylococcus aureus infections [abstract]. J Antimicrob Chemother 1999;44(suppl A):169. Abstract P593.
41. Srinath L, Feger C, Richard M-P, et al. Efficacy and safety of quinupristin/dalfopristin (Synercid) for treatment of methicillin-resistant Staphylo-coccus aureus infections [abstract]. Proceedings of the Fifth International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones, Seville, Spain, Jan. 26-28, 2000.
42. Raad I, Bompart F, Hachem R. Prospective, randomized dose-ranging open Phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia. Eur J Clin Microbiol Dis 1999;18: 199-202.
43. Jarvis WR, Martone WJ. Predominant pathogens in hospital infections. J Antimicrob Chemother 1992;29(suppl A):19-24.
44. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe: results of the European Prevalence of Infection in Intensive Care Study. JAMA 1995;274:639-644.
45. Fagon J-Y, Patrick H, Haas DW, et al. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/ dalfopristin versus vancomycin. Am J Respir Crit Care Med 2000;161:753-762.
46. Lavin BS, Pluim JL, Gray SL, et al. Efficacy and safety of treatment of elderly patients with quinupristin/dalfopristin (Synercid) [abstract]. Proceedings of the Fifth International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones, Seville, Spain, Jan. 26-28,2000.
47. Loeffler AM, Dorr MB, Prokocimer P, et al. Efficacy and safety of treatment of pediatric patients with quinupristin/dalfopristin [abstract]. Proceedings of the Fifth International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones, Seville, Spain, Jan. 26-28, 2000.
48. Bompart F, Dorr MB, Bekele T, et al. Overview of the safety and tolerability of quinupristin/dalfopristin (Synercid, RP 59500) in the global development program [abstract]. Proceedings of the 20th International Congress of Chemotherapy, Sydney, Australia, June 29-July 3, 1997. Abstract 846.
49. Zyvox, Linezolid Injection, Tablets, and for Oral Suspension Package Insert. April 2000.
50. Shinabarger DL, Marotti KR, Murray RW, et al. Mechanism of action of the oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother 1997; 41:2132-2136.
51. Swaney SM, Aoki H, Ganozza MC, et al. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998;42:3251-3255.
52. Diekema DJ, Jones RN. Oxazolidinones: a review. Drugs 2000;59:7-16.
53. Zurenko GE, Yagi HB, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996;40:839-845.
54. Jones RN, Johnson DM, Erwin ME. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Antimicrob Agents Chemother 1996;40: 720-726.
55. Mulazimoglu L, Drenning SD, Yu VL. In vitro activities of two novel oxazolidinones (U-100592 and U-100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1996;40:2428-2430.
56. Jorgensen JH, McElmeel ML, Trippy CW. In vitro activities of the oxazolidinone antibiotic U-100592 and U-100766 against Staphylococcus aureus and coagnlase-negative Staphylococcus species Antimicrob Agents Chemother 1997;41: 465-467.
57. Rybak JM, Cappelletty DM, Moldovan T, et al. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis and Enterococcus faecium. Antimicrob Agents Chemother 1998;42:721-724.
58. Spangler SK, Jacobs MR, Appelbaum PC. Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two oxazo-lidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillinsusceptible and -resistant pneumococci. Antimicrob Agents Chemother 1996;40:481-484.
59. Mason EO, Lambreth LB, Kaplan SL. In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of S. pneumoniae. Antimicrob Agents Chemother 1996;40:1039-1040.
60. Mercier RC, Penzak SR, Rybak MJ. In vitro activities of an investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1997;41: 2573-2575.
61. Bostic GD, Perri MB, Thal LA, et al. Comparative in vitro and bactericidal activity of oxazolidinone antibiotic against multidrug-resistant enterococci. Diagn Microbiol Infect Dis 1998; 30:109-112.
62. Eliopoulos GM, Wennersten CB, Gold HS, et al. In vitro activities of new oxazolidinone antimicrobial agents against enterococci. Antimicrob Agents Chemother 1996;40:1745-1747.
63. Yagi BH, Zurenko GE. In vitro activity of linezolid and eperezolid, two novel oxazolidinone antimicrobial agents, against anaerobic bacteria. Anaerobe 1997;3:301-306.
64. Steele M, Schneider B, Holloway W. Linezolid, an new oxazolidinone, has excellent activity in vitro against Listeria monocyfogenes [abstract]. General Meeting of the American Society for Microbiology, 1999:160.
65. Data on file, Upjohn Company, 1997.
66. Salmon SA, Portis EL, Case CA, et al. Minimum inhibitory concentration determinations for oxazolidinone antimicrobial agents and comparator agents against strains of Rhodococcus equi Abstract E-129. In: Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept. 24-27, 1998. Washington, DC: American Society for Microbiology, 1998.
67. Brown BA, Ward SC, Mann L, et al. In vitro activity of linezolid against multiple species of Nocardia: a new drug of choice for a difficult disease? Poster U-57. Program and Abstracts of the 100th General Meeting of the American Society for Microbiology, Los Angeles, CA, May 21-25, 2000.
68. Buchannan L, Dileto-Fang, C, Dailey C, et al. Antimicrobial effects of linezolid and vancomycin in experimental endocarditis [abstract]. Proceedings of the 37th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA, Nov. 18-21, 1999:52. Clin Infect Dis 1999;29: 975.
69. Buchannan L, Dileto-Fang, C, Dailey C, et al. Antimicrobial effects of linezolid and vancomycin in experimental endocarditis [abstract]. Proceedings of the 37th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA, Nov. 18-21, 1999:52. Clin Infect Dis 1999;29: 975.
70. Kaatz GW, Seo SM. In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1996;40:799-801.
71. Swaney SM, Shinabarger DL, Schaadt RD, et al. Oxazolidinone resistance is associated with a mutation in the peptidyl transferase region of 23S rRNA. Abstract C-104. In: Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept. 24-27, 1998. Washington, DC: American Society for Microbiology, 1998.
72. Fines M, Leclercq R. Influence of mechanisms of resistance to antibiotics that bind to the 50S ribosomal subunit on the activity of linezolid against gram-positive organisms. Abstract C-183. Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, Sept. 26-29, 1999.
73. Zurenko G, Todd WM, Hafkin B, et al. Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid. Poster 848. Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, Sept. 26-29, 1999.
74. Gemell DG, Ford CW. Expression of virulence factors by gram-positive cocci exposed to sub-MIC levels of linezolid. Abstract BUS. Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, Sept. 26-29, 1999.
75. Andes D, Van Ogtrop ML, Craig WA. Pharmacodynamic activity of a new oxazolidinone, linezolid, in an animal model of infection. Abstract CA-3. Proceedings of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, Sept. 24, 1998.
76. Data on file. Zyvox new drug application clinical study. Item 7. Microbiology. 1999.
77. Sweeney MT, Baldwin KF, Zurenko G. In vitro activity of linezolid combined with other antibacterial agents. Poster 1252. Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, Sept. 26-29, 1999.
78. Johnson RA, Haan DE, James CA, et al. Determination of linezolid, PNU-100766, in human plasma and urine using high-performance liquid chromatography with ultraviolet detection. Pharm Res 1997;14:S374.
79. Stalker DJ, Kearns GL, James L, et al. Pharmacokinetics of linezolid in pediatric patients. Clin Infect Dis 1998;27:1061.
80. Bruer MI, Stalker DJ, Aronoff G, et al. Pharmacokinetics of linezolid in subjects with varying degrees of renal function and on dialysis. J Invest Med 1998;46:276A.
81. Bruer M, Stalker D, Aronoff G, et al. Population pharmacokinetics of linezolid in subjects with a range of renal function. Clin Pharmacol Ther 1999;65:162.
82. Hendershot PE, Jungbluth GL, Cammarata SK, et al. Pharmacokinetics of linezolid in patients with liver disease. J Antimicrob · Chemother 1999;44(suppl A):55.
83. Jungbluth GL, Lasher ST, Hopkins NK, et al. Linezolid and aztreonam: a pharmacokinetic evaluation of intravenous coadministration in healthy volunteers. Clin Infect Dis 1997;25:487.
84. Laher S, Jungbluth G, Hopkins N. A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam. J Clin Pharmacol 1999;39:1277-1282.